{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:20:50Z","timestamp":1780514450182,"version":"3.54.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,12]]},"DOI":"10.7759\/cureus.106899","type":"journal-article","created":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T17:36:41Z","timestamp":1776015401000},"source":"Crossref","is-referenced-by-count":1,"title":["Bupropion Toxicity Presenting As Alcohol Withdrawal Syndrome: A Case Report"],"prefix":"10.7759","author":[{"given":"Darwin","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Faradji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Frangenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Haq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"U.S. Food and Drug Administration. wellbutrin XL (bupropion hydrochloride extended-release tablets) prescribing information. (2022). Accessed: April 1, 2026: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/021515s044lbl.pdf."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4088\/pcc.v06n0403","article-title":"A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor","volume":"6","author":"Stahl SM","year":"2004","unstructured":"Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry. 2004, 6:159-66. 10.4088\/pcc.v06n0403","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1177\/2045125316629071","article-title":"Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant","volume":"6","author":"Patel K","year":"2016","unstructured":"Patel K, Allen S, Haque MN, Angelescu I, Baumeister D, Tracy DK. Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant. Ther Adv Psychopharmacol. 2016, 6:99-144. 10.1177\/2045125316629071","journal-title":"Ther Adv Psychopharmacol"},{"key":"ref4","article-title":"Bupropion toxicity","author":"Alberter AA","year":"2026","unstructured":"Alberter AA, Chambers AJ, Schaffer DH. Bupropion toxicity. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2026."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1080\/03602532.2019.1620763","article-title":"Pharmacokinetic and pharmacodynamic of bupropion: integrative overview of relevant clinical and forensic aspects","volume":"51","author":"Costa R","year":"2019","unstructured":"Costa R, Oliveira NG, Dinis-Oliveira RJ. Pharmacokinetic and pharmacodynamic of bupropion: integrative overview of relevant clinical and forensic aspects. Drug Metab Rev. 2019, 51:293-313. 10.1080\/03602532.2019.1620763","journal-title":"Drug Metab Rev"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2024.2412423","article-title":"2023 annual report of the National Poison Data System\u00ae (NPDS) from America's Poison Centers\u00ae: 41st annual report","volume":"62","author":"Gummin DD","year":"2024","unstructured":"Gummin DD, Mowry JB, Beuhler MC, et al.. 2023 annual report of the National Poison Data System\u00ae (NPDS) from America's Poison Centers\u00ae: 41st annual report. Clin Toxicol (Phila). 2024, 62:793-1027. 10.1080\/15563650.2024.2412423","journal-title":"Clin Toxicol (Phila)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2019.1699658","article-title":"Clinical characteristics and outcomes associated with bupropion overdose: a Canadian perspective","volume":"58","author":"Stewart E","year":"2020","unstructured":"Stewart E, Grewal K, Hudson H, Thompson M, Godwin J. Clinical characteristics and outcomes associated with bupropion overdose: a Canadian perspective. Clin Toxicol (Phila). 2020, 58:837-42. 10.1080\/15563650.2019.1699658","journal-title":"Clin Toxicol (Phila)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1535-7511.2005.00071.x","article-title":"Update on the neurobiology of alcohol withdrawal seizures","volume":"5","author":"Rogawski MA","year":"2005","unstructured":"Rogawski MA. Update on the neurobiology of alcohol withdrawal seizures. Epilepsy Curr. 2005, 5:225-30. 10.1111\/j.1535-7511.2005.00071.x","journal-title":"Epilepsy Curr"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12671","article-title":"Alcohol withdrawal syndrome: mechanisms, manifestations, and management","volume":"135","author":"Jesse S","year":"2017","unstructured":"Jesse S, Br\u00e5then G, Ferrara M, et al.. Alcohol withdrawal syndrome: mechanisms, manifestations, and management. Acta Neurol Scand. 2017, 135:4-16. 10.1111\/ane.12671","journal-title":"Acta Neurol Scand"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1989.tb00737.x","article-title":"Assessment of alcohol withdrawal: the revised Clinical Institute Withdrawal Assessment for Alcohol scale (CIWA-Ar)","volume":"84","author":"Sullivan JT","year":"1989","unstructured":"Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM. Assessment of alcohol withdrawal: the revised Clinical Institute Withdrawal Assessment for Alcohol scale (CIWA-Ar). Br J Addict. 1989, 84:1353-7. 10.1111\/j.1360-0443.1989.tb00737.x","journal-title":"Br J Addict"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2013.06.012","article-title":"Etiology and therapeutic approach to elevated lactate levels","volume":"88","author":"Andersen LW","year":"2013","unstructured":"Andersen LW, Mackenhauer J, Roberts JC, Berg KM, Cocchi MN, Donnino MW. Etiology and therapeutic approach to elevated lactate levels. Mayo Clin Proc. 2013, 88:1127-40. 10.1016\/j.mayocp.2013.06.012","journal-title":"Mayo Clin Proc"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-014-7369-9","article-title":"Postictal serum creatine kinase for the differential diagnosis of epileptic seizures and psychogenic non-epileptic seizures: a systematic review","volume":"262","author":"Brigo F","year":"2015","unstructured":"Brigo F, Igwe SC, Erro R, et al.. Postictal serum creatine kinase for the differential diagnosis of epileptic seizures and psychogenic non-epileptic seizures: a systematic review. J Neurol. 2015, 262:251-7. 10.1007\/s00415-014-7369-9","journal-title":"J Neurol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1369-1600.2009.00185.x","article-title":"Phosphatidylethanol: normalization during detoxification, gender aspects and correlation with other biomarkers and self-reports","volume":"15","author":"Wurst FM","year":"2010","unstructured":"Wurst FM, Thon N, Aradottir S, et al.. Phosphatidylethanol: normalization during detoxification, gender aspects and correlation with other biomarkers and self-reports. Addict Biol. 2010, 15:88-95. 10.1111\/j.1369-1600.2009.00185.x","journal-title":"Addict Biol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200241140-00003","article-title":"Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence","volume":"41","author":"Eap CB","year":"2002","unstructured":"Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet. 2002, 41:1153-93. 10.2165\/00003088-200241140-00003","journal-title":"Clin Pharmacokinet"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2013.07.001","article-title":"Evaluation of metabolite\/drug ratios in blood and urine as a tool for confirmation of a reduced tolerance in methadone-related deaths in Denmark","volume":"133","author":"Nielsen MK","year":"2013","unstructured":"Nielsen MK, Johansen SS, Linnet K. Evaluation of metabolite\/drug ratios in blood and urine as a tool for confirmation of a reduced tolerance in methadone-related deaths in Denmark. Drug Alcohol Depend. 2013, 133:447-51. 10.1016\/j.drugalcdep.2013.07.001","journal-title":"Drug Alcohol Depend"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2004.02.017","article-title":"Intentional bupropion overdoses","volume":"27","author":"Shepherd G","year":"2004","unstructured":"Shepherd G, Velez LI, Keyes DC. Intentional bupropion overdoses. J Emerg Med. 2004, 27:147-51. 10.1016\/j.jemermed.2004.02.017","journal-title":"J Emerg Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2008.07.004","article-title":"Incidence and onset of delayed seizures after overdoses of extended-release bupropion","volume":"27","author":"Starr P","year":"2009","unstructured":"Starr P, Klein-Schwartz W, Spiller H, Kern P, Ekleberry SE, Kunkel S. Incidence and onset of delayed seizures after overdoses of extended-release bupropion. Am J Emerg Med. 2009, 27:911-15. 10.1016\/j.ajem.2008.07.004","journal-title":"Am J Emerg Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1081\/clt-200051867","article-title":"Position paper: single-dose activated charcoal","volume":"43","author":"Chyka PA","year":"2005","unstructured":"Chyka PA, Seger D, Krenzelok EP, Vale JA. Position paper: single-dose activated charcoal. Clin Toxicol (Phila). 2005, 43:61-87. 10.1081\/clt-200051867","journal-title":"Clin Toxicol (Phila)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1081\/clt-200035932","article-title":"Position paper: whole bowel irrigation","volume":"42","year":"2004","unstructured":"Position paper. whole bowel irrigation. J Toxicol Clin Toxicol. 2004, 42:843-54. 10.1081\/clt-200035932","journal-title":"J Toxicol Clin Toxicol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2019.11.029","article-title":"Bupropion overdose complicated by cardiogenic shock requiring vasopressor support and lipid emulsion therapy","volume":"58","author":"Herrman NW","year":"2020","unstructured":"Herrman NW, Kalisieski MJ, Fung C. Bupropion overdose complicated by cardiogenic shock requiring vasopressor support and lipid emulsion therapy. J Emerg Med. 2020, 58:e47-50. 10.1016\/j.jemermed.2019.11.029","journal-title":"J Emerg Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/475794-bupropion-toxicity-presenting-as-alcohol-withdrawal-syndrome-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T17:36:42Z","timestamp":1776015402000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/475794-bupropion-toxicity-presenting-as-alcohol-withdrawal-syndrome-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,12]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.106899","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,12]]}}}